Long oppertunity HALO Halozyme Therapeutics Inc (Mid-Term)

Company showing a great increase in fundamental strength and many good highlights
Fundamental
- Expect to strongly grow 50-70% Cashflow per share.
- Expect to 20% grow in one year.
- Turnover is rapidly growing.
Fundamental Analysis

Thông báo miễn trừ trách nhiệm